

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4362080

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
THE MEDICINES COMPANY	12/02/2016
RECEIVING PARTY DATA	
Name:	CHIESI FARMACEUTICI S.P.A.
Street Address:	VIA PALERMO, 26A
City:	PARMA
State/Country:	ITALY
Postal Code:	43122
PROPERTY NUMBERS Total: 2	
Property Type	Number
PCT Number:	US1531470
PCT Number:	US0943820
CORRESPONDENCE DATA	
Fax Number:	(412)343-5787
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	docket@beckthomas.com
Correspondent Name:	BECK & THOMAS, P.C.
Address Line 1:	1575 MCFARLAND ROAD
Address Line 2:	SUITE 100
Address Line 4:	PITTSBURGH, PENNSYLVANIA 15216
ATTORNEY DOCKET NUMBER:	160204
NAME OF SUBMITTER:	ANTONELLE PICCIRILLI
SIGNATURE:	/Antonelle Piccirilli/
DATE SIGNED:	04/11/2017
Total Attachments: 2	
source=00054863#page1.tif	
source=00054863#page2.tif	

ASSIGNMENT

Whereas, THE MEDICINES COMPANY, a Delaware corporation located at 8 Sylvan Way Parsippany, NJ 07054 (US) [ASSIGNOR] owns certain new and useful inventions and improvements in the following patent applications (collectively "The Applications"):

CLEVIDIPINE NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS

THEREOF, International Patent Application Serial Number PCT/US2015/031470, filed on May 19, 2015, which claims priority to United States Provisional Patent Application No. 62/000,119 filed on May 19, 2014;

PHARMACEUTICAL FORMULATIONS COMPRISING HIGH PURITY CANGRELOR AND METHODS FOR PREPARING AND USING THE SAME, U.S. Patent Application Serial Number 15/188,420, which is a continuation of United States Patent Application No. 15/049,727 filed on February 22, 2016, now United States Patent No. 9,439,921, which is a continuation of United States Patent Application No. 14/796,368 filed on July 10, 2015, now United States Patent No. 9,295,687, which claims priority to United States Provisional Patent Application No. 62/103,136 filed on January 14, 2015; and

MAINTENANCE OF PLATELET INHIBITION DURING ANTIPLATELET THERAPY, U.S. Patent Application Serial Number 15/136,979, which is a continuation of United States Patent Application No. 14/269,429, filed on May 5, 2014, now United States Patent No. 9,320,754, which is a continuation of United States Patent Application No. 13/954,821, filed on July 30, 2013, now United States Patent No. 8,716,261, which is a continuation of United States Patent Application No. 13/931,287, filed on June 28, 2013, which is a continuation-in-part of United States Patent Application No. 13/209,271 filed on August 12, 2011, which is a continuation-in-part of United States Patent Application No. 12/990,332 filed on August 15, 2011, now United States Patent No. 8,871,736, which is a national stage entry of CT/US09/043820, filed on May 13, 2009, which claims priority to United States Provisional Patent Application No. 61/127,424 filed on May 13, 2008.

AND CHIESI FARMACEUTICI S.p.a., an Italian company located at Via Palermo, 26A - 43122 Parma (IT) [ASSIGNEE], wishes to acquire the entire right, title, and interest in and to The Applications and the inventions and improvements therein disclosed;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR assigns, sells, transfers, and sets over unto the ASSIGNEE the entire right, title, and interest in and to The Applications and the inventions and improvements therein disclosed for the United States and all foreign countries and any Letters Patent which may issue therefore in the United States and all foreign countries and all national phase patent applications,

divisionals, reissues, continuations, continuations in part, renewals, and/or extensions thereof including all priority rights under the International Convention associated therewith for each country and the Union, the ASSIGNEE to have and to hold the interests assigned to the full ends of the terms of the Letters Patent and any and all national phase patent applications, divisionals, reissues, continuations, continuations in part, renewals, and/or extensions thereof, respectively, as fully and entirely as the same would have been held and enjoyed by us had this Assignment not been made.]

The parties acknowledge that this Assignments effective date is June 21, 2016.

ASSIGNOR:

By: _____




THE MEDICINES COMPANY

Executed December 2, 2016

NOTARY PUBLIC

STATE OF _____

COUNTY OF _____



Before me, a Notary Public in and for the said County and State, Matthew C. Bazley personally appeared and acknowledged that he is the person who executed the foregoing ASSIGNMENT and acknowledged it to be his free and voluntary act.

Witness my hand and notarial seal this 2nd day of December, 2016.

Notary Public



(Notarial Seal)

Rosa DelValle
ID # 2113983
NOTARY PUBLIC OF NEW JERSEY
Commission Expires 3/19/2020